| Effects of Retinoids on CYP2D6 Activity During Pregnancy (NCT03117660) | University of Washington | 2017-07-25 |
| A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer (NCT03081702) | University Health Network, Toronto | 2017-07-25 |
| Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors (NCT03175497) | Taizhou EOC Pharma Co., Ltd. | 2017-07-25 |
| Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia (NCT03132454) | M.D. Anderson Cancer Center | 2017-07-25 |
| Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects. (NCT03231124) | LEO Pharma | 2017-07-25 |
| Daprodustat Hepatic Impairment Study (NCT03223337) | GlaxoSmithKline | 2017-07-24 |
| The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors (NCT03182673) | Jiangsu HengRui Medicine Co., Ltd. | 2017-07-24 |
| A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03137758) | Pellficure Pharmaceuticals, Inc | 2017-07-24 |
| Influence of Oxytocin on Resting State Neurophysiological Measures (NCT03255148) | KU Leuven | 2017-07-24 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas (NCT03220347) | Celgene | 2017-07-24 |
| Bexagliflozin Drug/Drug Interaction Study With Digoxin (NCT03197324) | Theracos | 2017-07-24 |
| Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects (NCT06025851) | ChemomAb Ltd. | 2017-07-24 |
| Influence of Oxytocin on Neurophysiological Responses to Live Faces (NCT03272321) | KU Leuven | 2017-07-24 |
| Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) (NCT03109080) | Institut Curie | 2017-07-24 |
| A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma (NCT03150862) | BeiGene USA, Inc. | 2017-07-24 |
| Single Dose CHG Pharmacokinetic Study (NCT03331263) | Medline Industries | 2017-07-21 |
| A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects (NCT03304964) | Foresee Pharmaceuticals Co., Ltd. | 2017-07-21 |
| Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer (NCT03943043) | Istituto Clinico Humanitas | 2017-07-21 |
| A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants (NCT03228433) | Takeda | 2017-07-21 |
| Salsalate in Patients Mild to Moderate Alzheimer's Disease (NCT03277573) | Adam Boxer | 2017-07-21 |
| Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (NCT03214250) | Parker Institute for Cancer Immunotherapy | 2017-07-21 |
| Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma (NCT03143985) | Koen van Besien | 2017-07-21 |
| Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer (NCT03073395) | Five Eleven Pharma, Inc. | 2017-07-21 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants (NCT03224325) | Neurocrine Biosciences | 2017-07-21 |
| Phase I Study of SPH1188-11 in NSCLC (NCT03231475) | Shanghai Pharmaceuticals Holding Co., Ltd | 2017-07-21 |
| Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib (NCT03220191) | Pfizer | 2017-07-21 |
| Re-treatment From a Phase I Study of MSC-AFP in Patients With Perianal Fistulas (NCT03209700) | William A. Faubion, M.D. | 2017-07-20 |
| A Study of ADR-001 in Patients With Liver Cirrhosis (NCT03254758) | Rohto Pharmaceutical Co., Ltd. | 2017-07-20 |
| State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With Deep Brain Stimulation (DBS) (NCT02709148) | University of Minnesota | 2017-07-20 |
| Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA (NCT03307941) | Jules Bordet Institute | 2017-07-20 |
| Phase IB/II Study of NRT Combined With Radiotherapy for Advanced HCC (NCT03199807) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2017-07-20 |
| Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases (NCT03239756) | Jiangsu T-Mab Biopharma Co.,Ltd | 2017-07-20 |
| Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer (NCT03054038) | Vanderbilt-Ingram Cancer Center | 2017-07-20 |
| Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects (NCT03237988) | Corvus Pharmaceuticals, Inc. | 2017-07-20 |
| Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma (NCT02780609) | H. Lee Moffitt Cancer Center and Research Institute | 2017-07-20 |
| Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants (NCT03325075) | ModernaTX, Inc. | 2017-07-19 |
| Pharmacokinetics and Metabolism Study in Healthy Male Participants (NCT03247283) | Bristol-Myers Squibb | 2017-07-19 |
| Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma (NCT03024489) | Mahidol University | 2017-07-19 |
| PK and Safety Study of HCP1102, HGP0813 and HGP1408 (NCT03371849) | Hanmi Pharmaceutical Company Limited | 2017-07-19 |
| A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics (NCT03099330) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-07-19 |
| Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) (NCT03136185) | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 2017-07-18 |
| A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 (NCT03152318) | Dana-Farber Cancer Institute | 2017-07-18 |
| Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months (NCT03561181) | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 2017-07-18 |
| A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer (NCT03246854) | National Health Research Institutes, Taiwan | 2017-07-18 |
| A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib (NCT03222310) | Hoffmann-La Roche | 2017-07-18 |
| The Modular Protocol for Mental Health (MPMH) (NCT03143634) | Medical Research Council Cognition and Brain Sciences Unit | 2017-07-18 |
| A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) (NCT03075904) | Alexion Pharmaceuticals, Inc. | 2017-07-18 |
| A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients (NCT02869243) | Stemgen | 2017-07-18 |
| This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood (NCT03210272) | Boehringer Ingelheim | 2017-07-18 |
| The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment (NCT02553603) | The University of Texas Medical Branch, Galveston | 2017-07-18 |
| Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer (NCT03150056) | GlaxoSmithKline | 2017-07-18 |
| Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. (NCT03150329) | City of Hope Medical Center | 2017-07-18 |
| Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial (NCT03173976) | Mohammed Milhem | 2017-07-18 |
| BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect (NCT03212586) | Bayer | 2017-07-18 |
| Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease (NCT03225833) | Wave Life Sciences USA, Inc. | 2017-07-17 |
| Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss (NCT03131908) | M.D. Anderson Cancer Center | 2017-07-17 |
| A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers (NCT04555824) | Beijing Northland Biotech. Co., Ltd. | 2017-07-17 |
| A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 (NCT03275740) | Pfizer | 2017-07-17 |
| This Study is Done in Healthy Chinese and Japanese Volunteers; it Looks at How BI 690517 is Taken up in the Body and How Well it is Tolerated (NCT03206632) | Boehringer Ingelheim | 2017-07-17 |
| Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis (NCT03251092) | Proteostasis Therapeutics, Inc. | 2017-07-17 |
| Gene Therapy in Patients With Mucopolysaccharidosis Disease (NCT03173521) | Fondazione Telethon | 2017-07-17 |
| A Sunscreen Based on Bioadhesive Nanoparticles (NCT02668536) | Yale University | 2017-07-17 |
| A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China (NCT03235778) | Yiling Pharmaceutical Inc. | 2017-07-17 |
| A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy Participants (NCT03220126) | Eli Lilly and Company | 2017-07-17 |
| Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC) (NCT03210246) | Bayer | 2017-07-17 |
| CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1) (NCT05164003) | Medy-Tox | 2017-07-17 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma (NCT03010358) | Alexey Danilov, MD | 2017-07-17 |
| Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease (NCT03225846) | Wave Life Sciences USA, Inc. | 2017-07-17 |
| AFM13 in Relapsed/Refractory Cutaneous Lymphomas (NCT03192202) | Ahmed Sawas | 2017-07-17 |
| Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer (NCT05535569) | Yonsei University | 2017-07-17 |
| Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects (NCT03524157) | Laboratorios Sophia S.A de C.V. | 2017-07-17 |
| Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers (NCT05765357) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-07-16 |
| A Dose Escalating Study to Assess the Safety and Tolerability of GT-001 (NCT03490786) | Gila Therapeutics, Inc. | 2017-07-16 |
| Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients (NCT03026231) | The University of Texas Health Science Center, Houston | 2017-07-15 |
| Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis (NCT03169894) | Avalo Therapeutics, Inc. | 2017-07-14 |
| A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis (NCT03210961) | Pfizer | 2017-07-14 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 (NCT02650986) | Roswell Park Cancer Institute | 2017-07-14 |
| Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers (NCT03254732) | Polaris Group | 2017-07-14 |
| A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors (NCT03203876) | Bristol-Myers Squibb | 2017-07-14 |
| Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) (NCT03153202) | Joshua Brody | 2017-07-14 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy Subjects (NCT03217604) | Pfizer | 2017-07-13 |
| Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics (NCT03162250) | Genentech, Inc. | 2017-07-13 |
| Open-label Clinical Trial of Lacosamide in ALS (NCT03186040) | Chiba University | 2017-07-13 |
| Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment (NCT03196206) | Bristol-Myers Squibb | 2017-07-13 |
| Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis (NCT03006146) | Children's Hospital Medical Center, Cincinnati | 2017-07-13 |
| Two-period 21 Day Cross-over Study to Compare the Pharmacokinetics of Tiotropium From Two Inhalers (NCT03246581) | Kindeva Drug Delivery | 2017-07-13 |
| AK-R215 Pharmacokinetic Study Phase I (NCT03321318) | Alvogen Korea | 2017-07-13 |
| Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects (NCT03234751) | AdventHealth Translational Research Institute | 2017-07-13 |
| Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug (NCT03235726) | GlaxoSmithKline | 2017-07-13 |
| Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors (NCT03182257) | Ono Pharmaceutical Co., Ltd. | 2017-07-12 |
| PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck (NCT02819752) | Royal Marsden NHS Foundation Trust | 2017-07-12 |
| Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma (NCT03316144) | Shanghai Junshi Bioscience Co., Ltd. | 2017-07-12 |
| Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer (NCT03144778) | M.D. Anderson Cancer Center | 2017-07-12 |
| Fecal Microbiota Transplantation for Steroid Resistant and Steroid Dependent Gut Acute Graft Versus Host Disease (NCT03214289) | Sheba Medical Center | 2017-07-12 |
| Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD) (NCT03137082) | Stony Brook University | 2017-07-12 |
| Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma (NCT02992483) | Novartis Pharmaceuticals | 2017-07-12 |
| A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal Function (NCT03189498) | Janssen Pharmaceutica N.V., Belgium | 2017-07-11 |
| A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection (NCT03174795) | Hoffmann-La Roche | 2017-07-11 |
| Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (NCT03044613) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-07-11 |
| A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer (NCT02963051) | Daniel George, MD | 2017-07-11 |